Disease | Micro RNA | Tissue/ Cell line | MicroRNA regulation | Pathway | More Details | References |
---|---|---|---|---|---|---|
T-cell acute lymphoblastic leukemia | hsa-miR-19 | Jurkat, MOLT-4 | Up | NF-Kappa B signaling pathway | hsa-miR-19 regulates the expression of CYLD and controls NF-Kappa B expression in downstream signaling pathway in T-cell acute lymphoblastic leukemia. | Ye et al., 2012 |
Gastric cancer | hsa-miR-20a | Gastric cancer tissue | Up | NF-Kappa B signaling pathway | MicroRNA-20a directly suppresses the expression of CYLD, leads to activation of the NF-Kappa B signaling pathway and the downstream targets, livin and survivin, which potentially induces gastric cancer chemoresistance. | Zhu et al., 2016 |
Breast cancer | hsa-miR-362 | Breast | Up | NF-Kappa B signaling pathway | MicroRNA-362 regulates breast cancer cell proliferation, migration and invasion through NF-Kappa B signaling pathway. | Ni et al., 2016 |
Hepatocellular carcinoma | hsa-miR-362 | Hepatocyte | Up | NF-Kappa B signaling pathway | hsa-miR-362 acts through CYLD to activate the NF-Kappa B signaling pathway, which promotes hepatocellular carcinoma cell growth and metastasis. | Ni et al., 2015 |